Oncodesign Precision Medicine Société anonyme (ZR8) Stock Overview
A biopharmaceutical company, engages in the precision medicine business. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 3/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
ZR8 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
Oncodesign Precision Medicine Société anonyme Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.47 |
| 52 Week High | €1.26 |
| 52 Week Low | €0.26 |
| Beta | -0.70 |
| 1 Month Change | 18.75% |
| 3 Month Change | 59.40% |
| 1 Year Change | -54.76% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -54.72% |
Recent News & Updates
Recent updates
Shareholder Returns
| ZR8 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -3.7% | 0.2% | 2.7% |
| 1Y | -54.8% | -29.1% | 14.6% |
Return vs Industry: ZR8 underperformed the German Biotechs industry which returned -29.1% over the past year.
Return vs Market: ZR8 underperformed the German Market which returned 14.6% over the past year.
Price Volatility
| ZR8 volatility | |
|---|---|
| ZR8 Average Weekly Movement | 27.6% |
| Biotechs Industry Average Movement | 10.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 12.3% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: ZR8's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: ZR8's weekly volatility has increased from 20% to 28% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 18 | Philippe Genne | www.oncodesign.com |
Oncodesign Precision Medicine Société anonyme, a biopharmaceutical company, engages in the precision medicine business. The company’s product pipeline consist of OPM-101, a potentially inhibitor of the RIPK2 target, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; OPM-102, a novel inhibitor that is in preclinical studies for the treatment of cancer; and OPM-201, a potential LRRK2 inhibitor, which is in Phase 1 clinical trial for the treatment of Parkinson’s disease. It is also developing drugs for the treatment of pancreatic and other cancers.
Oncodesign Precision Medicine Société anonyme Fundamentals Summary
| ZR8 fundamental statistics | |
|---|---|
| Market cap | €9.27m |
| Earnings (TTM) | €6.28m |
| Revenue (TTM) | €1.74m |
Is ZR8 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ZR8 income statement (TTM) | |
|---|---|
| Revenue | €1.74m |
| Cost of Revenue | -€7.58m |
| Gross Profit | €9.31m |
| Other Expenses | €3.03m |
| Earnings | €6.28m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.35 |
| Gross Margin | 536.76% |
| Net Profit Margin | 361.97% |
| Debt/Equity Ratio | -1,765.5% |
How did ZR8 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/05 17:15 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Oncodesign Precision Medicine Société anonyme is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Seynnaeve | Degroof Petercam Sponsored Research |